Loading…
Loading…
Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.
Universal Health Services, Inc. is rated Strong Buy due to undervaluation at 8x forward P/E and resilient earnings growth. Recent guidance cuts reflect mostly temporary challenges, with consolidated revenue and EBITDA still growing across both Acute Care and Behavioral Health segments. Medicaid reimbursement cuts are gradual and manageable, with management repositioning toward outpatient behavioral health and private payors.
Universal Health Services (UHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health Services (NYSE: UHS - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Universal Health Services to post earnings of $5.20 per share and revenue of $4.71 billion for the quarter. Investors can check the company's upcoming Q3 2026 earnings overview page
Universal Health Services, Inc. (NYSE: UHS) announced it will report Q3 2026 after the market close on Oct. 26, 2026 and hold its earnings call on Oct. 27.
Investors need to pay close attention to UHS stock based on the movements in the options market lately.
Universal Health Services (NYSE: UHS - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends. Institutional and Insider Ownership 86.0% of Universal Health
Shares of Universal Health Services, Inc. (NYSE: UHS - Get Free Report) have been given a consensus recommendation of "Hold" by the eighteen research firms that are presently covering the company, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company.